Bremelanotide (PT-141) significantly improved erectile function in men who had failed sildenafil treatment, in a double-blind placebo-controlled RCT — demonstrating the brain-acting melanocortin approach works where peripheral drugs fail.
Key findingSC bremelanotide significantly improved erectile responses in sildenafil-failure ED patients in a double-blind, placebo-controlled RCT — demonstrating
What the researchers found
SC bremelanotide significantly improved erectile responses in sildenafil-failure ED patients in a double-blind, placebo-controlled RCT — demonstrating melanocortin central mechanism (desire/arousal) rescues patients where PDE5 peripheral mechanism (blood flow) fails.
Why it matters
Relevant for pt-141, sexual-health.
How the study worked
RCT study.
What this study cannot tell us
See abstract.
How to read the evidence
strong evidence.
When this study was published
Published in 2008.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.
The Journal of urology, 179(3), 1066-71
Citation
Safarinejad, Mohammad Reza; Hosseini, Seyyed Yousof. (2008). Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.. The Journal of urology, 179(3), 1066-71. https://doi.org/10.1016/j.juro.2007.10.063